



ABN 53 075 582 740

**ASX ANNOUNCEMENT**  
**16 March 2021**

---

## **Bionomics Limited Completes Despatch of Entitlement Offer Booklet**

On Monday, 8 March 2021, Bionomics Limited (ASX: BNO) (**Bionomics** or **Company**), a clinical stage biopharmaceutical company, announced a pro rata non-renounceable 1-for-6 entitlement offer of new fully paid ordinary shares in the Company (**New Shares**) to raise approximately A\$20 million (before costs) (**Entitlement Offer**).

Bionomics is pleased to announce that it has completed the despatch of the offer booklet and personalised entitlement and acceptance form to Bionomics shareholders eligible to participate in the Entitlement Offer (**Offer Booklet**).

A letter to ineligible shareholders was despatched on Monday, 8 March 2021.

### **Further information**

Further details of the Entitlement Offer are set out in the Offer Booklet provided to the ASX on Monday, 8 March 2021.

### **Investor enquiries**

If you have any questions in relation to the Entitlement Offer, please contact the Bionomics Offer Information Line on 1300 556 161 (within Australia) or +61 3 9415 4000 (outside Australia) between 8.30 am and 5.00 pm (AEDT) Monday to Friday.

Nothing contained in this announcement constitutes investment, legal, tax or other advice. You should make your own assessment and consult your independent broker, solicitor, accountant, financial adviser, or other professional adviser in relation to the information in this announcement and any action to be taken on the basis of that information.

**AUTHORISED BY: DR ERROL DE SOUZA, EXECUTIVE CHAIRMAN**

### **FOR FURTHER INFORMATION PLEASE CONTACT:**

Mr Jack Moschakis  
Legal Counsel & Company Secretary  
Bionomics Limited  
31 Dalglish St,  
Thebarton, South Australia  
+61 8 8354 6100  
[jmoschakis@bionomics.com.au](mailto:jmoschakis@bionomics.com.au)

### **About Bionomics Limited**

Bionomics (ASX: BNO, OTCQB: BNOEF, Germany: AU000000BNO5) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates. Bionomics' lead drug candidate BNC210, currently in development for initiation of a second Phase 2 trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor. Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc (known as MSD outside the United States and Canada) with two drugs in early stage clinical trials for the treatment of cognitive deficits in Alzheimer's disease.

[www.bionomics.com.au](http://www.bionomics.com.au)

### **Factors Affecting Future Performance**

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.